Clinical trial · Observational
Genetic Susceptibility to Bladder Cancer
Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interviews | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants with Bladder Cancer
- description
- Patients diagnosed with superficial or muscle-invasive bladder cancer. Specimens, personal and follow-up telephone interviews will be collected and conducted.
- interventionNames
- Behavioral: Interviews
Primary outcomes (1)
- measure
- Comparison of mutagen sensitivity susceptibility assays that quantifies the number of lymphocytic chromatid breaks induced by in vitro exposure to bleomycin and the number of breaks induced by in vitro exposure to a tobacco carcinogen
- timeFrame
- After last subject has completed the study, up to 5 years
- description
- Mutagen sensitivity as measured by quantifying the number of lymphocytic chromatid breaks and comet tail moments induced by in vitro exposure to bleomycin (a radiomimetic agent) and benzo\[a\]pyrene diol epoxide (BPDE, a tobacco carcinogen) in bladder cancer cases in comparison to data for controls
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Subject has a histologically confirmed diagnosis of superficial or muscle-invasive bladder cancer * Subject is a Texas resident. * Subject can understand English or a qualified translator is available for the interview. * Subjects of any age, gender, or ethnicity are eligible to participate in the study. * Subject consents to participate in the study. Exclusion Criteria: * Subject has had prior treatment with systemic chemotherapy or radiotherapy in the past 6 months. * Subject has been diagnosed with superficial or muscle-invasive bladder cancer more than twelve months ago.
References
Publications (0)
Data not yet available